10-Q: Avidity Biosciences Acquired by Novartis for $72/Share

Avidity Biosciences announces its acquisition by Novartis AG for $72.00 per share in cash, alongside a spin-off of its early-stage cardiology programs.

Summary

• Avidity Biosciences, Inc. has entered into a definitive Merger Agreement to be acquired by Novartis AG for $72.00 per share in cash.
• In conjunction with the merger, Avidity will spin off its early-stage precision cardiology programs and certain collaboration agreements into a new entity, Bryce Therapeutics, Inc. (SpinCo).
• Avidity stockholders will receive 1 share of SpinCo common stock for every 10 shares of Avidity common stock held.
• The merger and spin-off transactions are anticipated to close in the first half of 2026.
• The company reported a net loss of $447.5 million for the nine months ended September 30, 2025, significantly higher than the $220.0 million loss for the same period in 2024.
• Collaboration revenue increased to $17.9 million for the nine months ended September 30, 2025, up from $7.9 million in the prior year, primarily due to a $10.0 million milestone payment from Eli Lilly and Company.
• Research and development expenses surged to $392.6 million for the nine months ended September 30, 2025, compared to $208.0 million in 2024, driven by clinical trial progression and manufacturing costs.
• General and administrative expenses also increased to $116.8 million for the nine months ended September 30, 2025, from $57.9 million in 2024, due to higher personnel and professional fees.
• Avidity's cash, cash equivalents, and marketable securities totaled $1.9 billion as of September 30, 2025, which is deemed sufficient to fund operations for at least 12 months.
• Positive clinical data was reported for del-zota (DMD44), del-desiran (DM1), and del-brax (FSHD), with multiple regulatory designations and FDA alignment on approval pathways.
• A commercial manufacturing agreement was signed with Lonza for minimum purchase obligations of $621.6 million from 2026-2028.

Sentiment

Score: 9

Explanation: The definitive acquisition by Novartis at a substantial cash premium, coupled with strong positive clinical trial data and regulatory progress for all lead programs, represents a highly favorable outcome for shareholders and validates the company's AOC platform. While operating losses increased, this is typical for a biotech in advanced clinical development and is overshadowed by the acquisition news. The risks associated with merger completion and SpinCo's future are present but do not negate the immediate positive impact of the acquisition.

Positives

• Definitive agreement for acquisition by Novartis AG at $72.00 per share in cash, representing a significant premium for shareholders.
• Positive pre-BLA meeting with the FDA for del-zota (DMD44), aligning on a clear path for potential accelerated approval submission in 2026.
• Del-zota demonstrated reversal of disease progression, statistically significant increases in dystrophin production (approx. 25% of normal, up to 58% total), and rapid reduction in creatine kinase levels (>80%) in the EXPLORE44 trial.
• Del-zota received Breakthrough Therapy designation and Rare Pediatric Disease designation from the FDA.
• Phase 3 HARBOR trial for del-desiran (DM1) is fully enrolled with 159 participants, indicating strong progress in clinical development.
• FDA alignment on accelerated and full approval pathways for del-brax (FSHD), with initiation of the global confirmatory Phase 3 FORTITUDE-3 study.
• Positive topline Phase 1/2 FORTITUDE data for del-brax showed consistent improvement in functional mobility, muscle strength, quality of life, and reductions in DUX4-regulated biomarkers.
• The FDA accepted cDUX as a surrogate endpoint for potential accelerated approval of del-brax.
• Significant cash, cash equivalents, and marketable securities of $1.9 billion provide strong liquidity and are expected to fund operations for at least 12 months.
• Increased collaboration revenue, including a $10.0 million clinical development milestone payment from Eli Lilly and Company.

Negatives

• Net loss more than doubled to $447.5 million for the nine months ended September 30, 2025, compared to $220.0 million in the prior year.
• Research and development expenses increased substantially by $184.6 million, reflecting high costs associated with clinical trials and manufacturing.
• General and administrative expenses rose by $58.9 million, indicating increased operational overhead.
• The company has an accumulated deficit of $1.3 billion as of September 30, 2025, and expects to continue incurring net losses.
• Cash used in operating activities significantly increased to $480.7 million for the nine months ended September 30, 2025, from $201.0 million in 2024.

Risks

• The pending acquisition by Novartis may not be completed within the anticipated timeframe or at all, which could adversely affect business, financial results, and operations.
• The price of common stock may decline if current market prices reflect an assumption that the Merger will be completed and it subsequently fails.
• Avidity could be required to pay Novartis a termination fee of $450 million if the Merger Agreement is terminated under specific circumstances (e.g., accepting a superior proposal).
• Failure to complete the Merger could result in negative publicity and negatively affect relationships with stockholders, employees, regulators, and business partners.
• The pendency of the Merger and Spin-Off could cause substantial disruptions, create uncertainty, and affect the ability to recruit or retain employees.
• Management's attention may be diverted from day-to-day operations due to the Merger and Spin-Off processes.
• Restrictions on business activities while the Merger Agreement is in effect could prevent Avidity from pursuing advantageous business opportunities or responding effectively to competitive pressures.
• Significant direct and indirect costs will be incurred in connection with the pending transaction, regardless of its completion.
• Litigation may arise in connection with the Merger or Spin-Off, which could be costly, time-consuming, and divert management's attention.
• Provisions in the Merger Agreement could discourage potential competing acquirers or result in lower offers due to the termination fee.
• The value of SpinCo Common Stock may not be as anticipated, and SpinCo as an independent company will be smaller, less diversified, and potentially more vulnerable to market conditions.
• Current stockholders will not be able to participate in any further upside to the portion of the business acquired by Novartis if the Merger is consummated.

Future Outlook

The company expects to continue incurring net losses into the foreseeable future as it advances product candidates and development programs. Existing cash, cash equivalents, and marketable securities are believed to be sufficient to fund operations for at least 12 months from the filing date. Future cash needs are planned to be financed through equity offerings, debt financings, or collaborations. The merger with Novartis and the spin-off are expected to close in the first half of 2026. The company plans for potential successive product launches for DMD, DM1, and FSHD starting in 2026, transitioning to a commercial organization.

Management Comments

• We completed a positive pre-BLA meeting with the FDA and aligned on a clear path forward for a planned BLA submission for potential accelerated approval of del-zota.
• We plan to submit to the FDA a protocol amendment for the HARBOR trial, which amendment will move the data cutoff date and related items from 30 weeks to 54 weeks. This change is a significant opportunity for patients and the HCP community as it will demonstrate the long-term efficacy and safety benefits of del-desiran.
• We believe that a larger safety database and longer efficacy data at 54 weeks will increase likelihood of demonstrating a treatment effect in a slowly progressing disease on multiple endpoints.
• We are advancing and expanding our innovative AOC pipeline to develop potential treatment options for people living with rare diseases across a wide range of therapeutic areas.
• We continue to execute on our global commercial infrastructure development as we plan for three potential successive product launches for DMD, DM1 and FSHD starting in 2026 and transition to the next stage as we advance our AOC technology in rare neuromuscular and precision cardiology, and next-generation innovations.

Industry Context

Avidity Biosciences operates in the highly specialized and competitive biopharmaceutical sector, focusing on RNA therapeutics for rare diseases. The acquisition by Novartis AG, a global pharmaceutical giant, underscores the increasing interest and validation of RNA-based therapies and targeted drug delivery platforms like Avidity's Antibody Oligonucleotide Conjugates (AOCs). The spin-off of early-stage cardiology programs into SpinCo reflects a strategic move to streamline the acquired entity's focus while allowing the spun-off assets to pursue independent development, a common practice in large pharmaceutical mergers to unlock value. The strong clinical data for its lead programs positions Avidity as a leader in developing treatments for Duchenne muscular dystrophy, myotonic dystrophy type 1, and facioscapulohumeral muscular dystrophy, areas with significant unmet medical needs. The FDA's Breakthrough Therapy and Fast Track designations highlight the potential of these therapies to address serious conditions more effectively than existing options.

Comparison to Industry Standards

• Del-zota data showed reversal of disease progression and unprecedented improvement compared to baseline and DMD44 natural history (Nat Hx) across multiple functional measures, including a 2.1-second improvement in 4-Stair Climb versus a 2.7-second decline in natural history (N=22 for Nat Hx; N=10 for del-zota).
• Del-zota-treated participants demonstrated a 0.7-second improvement in the 10-Meter Walk/Run Test, contrasting with a 1.5-second decline in the DMD44 natural history group (N=22 for Nat Hx; N=10 for del-zota).
• Time to Rise from Floor improved by 3.2 seconds for del-zota participants, while the natural history group declined by 1.6 seconds (N=19 for Nat Hx; N=6 for del-zota).
• North Star Ambulatory Assessment (NSAA) remained stable for del-zota participants, compared to a 2.4-point decline in the DMD44 natural history group (N=20 for Nat Hx; N=10 for del-zota).
• Performance of Upper Limb (PUL2) improved by 1.5 points with del-zota, whereas the natural history group declined by 0.7 points (N=27 for Nat Hx; N=17 for del-zota).
• Del-desiran data from the MARINA-OLE trial showed reversal of disease progression across multiple endpoints, including video hand opening time (vHOT), muscle strength, and activities of daily living, when compared to the END-DM1 natural history study population over one year.

Legal Proceedings

• The company is not currently subject to any material legal proceedings.
• Litigation may arise in connection with the Merger or the Spin-Off, which could be costly and divert management's attention.

Stakeholder Impact

• Shareholders: Will receive $72.00 per share in cash from Novartis and 1 share of SpinCo common stock for every 10 shares of Avidity common stock, representing a significant return and a speculative interest in the spun-off entity.
• Employees: May experience uncertainty about their roles following the consummation of both the Merger and Spin-Off, potentially affecting retention and motivation.
• Customers (patients): Benefit from accelerated development and potential market entry of promising RNA therapeutics for rare neuromuscular diseases.
• Collaborators (e.g., Eli Lilly, Bristol Myers Squibb): Existing collaboration agreements related to early-stage precision cardiology programs will be transferred to SpinCo, while other collaborations will continue under Novartis's ownership.
• Regulatory Authorities: Will continue to review BLA submissions and clinical trial data, with FDA alignment already achieved for accelerated approval pathways for key programs.
• Creditors: The company's strong cash position and the acquisition by a major pharmaceutical company likely enhance creditworthiness, though the spin-off creates a new, smaller entity.

Next Steps

• Complete the Merger with Novartis AG and the Spin-Off of Bryce Therapeutics, Inc. (SpinCo) in the first half of 2026.
• Submit a Biologics License Application (BLA) for potential accelerated approval of del-zota (DMD44) to the FDA in 2026.
• Submit protocol amendments to the IND for del-zota to generate additional data for BLA submission.
• Publish data analyses from the completed Phase 1/2 MARINA trial for del-desiran in the fourth quarter of 2025.
• Receive 54-week topline data readout from the global Phase 3 HARBOR study for del-desiran in the second half of 2026.
• Receive topline data from the FORTITUDE biomarker cohort for del-brax in the second quarter of 2026.
• Receive FORTITUDE-3 data readout and make global regulatory submissions for del-brax in 2028.
• Continue to build global commercial infrastructure for potential successive product launches for DMD, DM1, and FSHD starting in 2026.
• Manage minimum purchase obligations under the commercial manufacturing agreement with Lonza from 2026-2028.
• Begin payments for the Amended Sublease in April 2026.

Key Dates

Recommendation

The filing announces a definitive agreement for Avidity Biosciences to be acquired by Novartis AG for $72.00 per share in cash. This fixed cash consideration provides a clear upside for investors if the stock is currently trading below this price, presenting an arbitrage opportunity. Additionally, existing shareholders will receive shares in the spun-off entity, Bryce Therapeutics, Inc. (SpinCo), offering a speculative, long-term value component. Given the definitive nature of the agreement and the premium offered, a 'buy' recommendation is appropriate for investors seeking to capture the spread, assuming a high probability of deal completion.

Keywords

Avidity Biosciences, Novartis AG, Acquisition, Merger, Spin-Off, Bryce Therapeutics, RNA therapeutics, Antibody Oligonucleotide Conjugates, AOCs, Duchenne muscular dystrophy, DMD44, del-zota, Myotonic dystrophy type 1, DM1, del-desiran, Facioscapulohumeral muscular dystrophy, FSHD, del-brax, Clinical trials, Biopharmaceutical, SEC filing, 10-Q, Financial results, Biotech, Rare diseases, Orphan drug, Breakthrough Therapy, FDA approval, Lonza, Contract Manufacturing Organization